Sanofi (NASDAQ:SNY) said on Thursday its multiplemyeloma drug Sarclisa (isatuximab) met the primary endpoints of a late-stage trial. The drug is currently indicated for use in a combination ...
Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiplemyeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.
Sanofi’s Sarclisa (isatuximab) plus standard of care has been shown to extend the time that some multiplemyeloma patients remain stable without disease progression. This was demonstrated in a ...
Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...
Sanofi’s new multiplemyeloma drug Sarclisa (isatuximab) has been approved in the EU for relapsed/refractory disease, taking on Johnson & Johnson’s well-established blockbuster Darzalex. The ...